MARAVIROC in English translation

• maraviroc

Examples of using Maraviroc in Danish and their translations into English

Da maraviroc er moderat proteinbundet,
Since maraviroc is moderately protein bound,

Midazolam 7, 5 mg enkeltdosis(maraviroc 300 mg 2 gange dagligt) Naturmedicin.
Midazolam 7.5 mg Single Dose(maraviroc 300 mg BID) HERBAL PRODUCTS.

Af den samlede clearance for maraviroc, når maraviroc anvendes uden CYP3A4- hæmmere.
Renal clearance accounts for approximately 23% of total clearance of maraviroc when maraviroc is administered without CYP3A4 inhibitors.

Der er udført et massebalance/ ekskretionsforsøg med en enkeltdosis på 300 mg 14C- mærket maraviroc.
Elimination: a mass balance/ excretion study was conducted using a single 300 mg dose of 14C-labeled maraviroc.

mulig resistens over for maraviroc.
possible resistance to maraviroc.

kliniske data er sandsynligheden, for at maraviroc påvirker farmakokinetikken af samtidigt anvendte lægemidler, lav.
clinical data, the potential for maraviroc to affect the pharmacokinetics of coadministered medicinal products is low.

CELSENTRI bør ikke anvendes hos patienter, der kan være overfølsomme(allergiske) over for maraviroc, jordnødder, soja
CELSENTRI should not be used in patients who may be hypersensitive(allergic) to maraviroc, peanut, soya

I cellekultur var kombinationen af maraviroc og andre antiretrovirale lægemidler ikke antagonistisk med en række NRTI,
When used with other antiretroviral medicinal products in cell culture, the combination of maraviroc was not antagonistic with a range of NRTIs,

In vitro- resultater tyder på, at maraviroc kan hæmme P- glycoprotein i tarmen,
In vitro results indicate that maraviroc could inhibit P- glycoprotein in the gut

Hos patienter med CCR5- tropismevirus på tidspunktet for behandlingssvigt med CELSENTRI havde 22 ud af 58 patienter virus med reduceret følsomhed over for maraviroc.
In patients with CCR5-tropic virus at time of treatment failure with CELSENTRI, 22 out of 58 patients had virus with reduced sensitivity to maraviroc.

in vivo- forsøg viser, at maraviroc har et potentiale for at øge QTc- intervallet ved supraterapeutiske doser uden tegn på arrytmi.
in vivo studies showed that maraviroc has a potential to increase QTc interval at supratherapeutic doses with no evidence of arrhythmia.

Ved administration af maraviroc hos rotter ses thyroideaadenom, der er forbundet med adaptive leverændringer ved en systemisk eksponering, der er 21 gange den forventede humane dosis.
In rats, administration of maraviroc at a systemic exposure 21-times the expected human exposure produced thyroid adenomas associated with adaptive liver changes.

Maraviroc virker derimod ikke, når viruset i en blodprøve bindes til et andet protein, der kaldes CXCR4,
Maraviroc cannot work when the virus in a blood sample attaches to another protein called CXCR4,

Maraviroc er ikke mutagent
Maraviroc was not mutagenic

hvorfor nedsat nyrefunktion ikke forventes at påvirke eksponering for maraviroc signifikant.
hence renal impairment is not expected to significantly alter maraviroc exposures.

In vitro har maraviroc ingen aktivitet mod virus, der bruger CXCR4 som deres indtrædende co- receptor dual- tropisme
Maraviroc has no antiviral activity in vitro against viruses which can use CXCR4 as their entry co- receptor dual-tropic

Desuden viser samtidig anvendelse af CELSENTRI og lamivudin/ zidovudin ingen virkning af maraviroc på farmakokinetikken af lamivudin(primært renalt udskilt)
In addition, co-administration of CELSENTRI with lamivudine/ zidovudine showed no effect of maraviroc on lamivudine(primarily renally cleared)

Hos de patienter, der kun havde behandlingssvigt med R5- virus, kan maraviroc måske stadig betragtes som aktiv, hvis den maksimale procent- hæmningsværdi(MPI) er ≥ 95% Phenosense Entry assay.
In patients failing therapy with R5-virus only, maraviroc might be considered still active if the maximal percentage inhibition(MPI) value is≥ 95% Phenosense Entry assay.

Forsøg med humane levermikrosomer og rekombinante enzymsystemer viste, at maraviroc ved klinisk relevante koncentrationer ikke hæmmer nogen af de vigtige P450- enzymer CYP1A2,
Studies in human liver microsomes and recombinant enzyme systems have shown that maraviroc does not inhibit any of the major P450 enzymes at clinically relevant concentrations CYP1A2,

Tag ikke CELSENTRI hvis De er overfølsom(allergisk) over for maraviroc, jordnødder, soja
Do not take CELSENTRI if you are allergic(hypersensitive) to maraviroc or to peanut or soya